AZN - AstraZeneca PLC Stock Trading

AstraZeneca PLC(NYSE: AZN) stock trading description contact officers and directors.

About AstraZeneca PLC

Not available

Stock Information

AstraZeneca PLC Company Name:

AZN Stock Symbol:

NYSE Market:

Get AZN Alerts

News, Short Squeeze, Breakout and More Instantly...

AZN - ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer

Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s ENHERTU reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease AstraZeneca and Daiichi Sankyo’s ENHERTU ® (fam-trastuzumab deruxtecan-...
AZN - TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy Global SAFFRON Phase III trial evaluating this combination is underway Preliminary results from the SAVANNAH Phase II trial showed that T...
AZN - HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase&#

— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase III trial evaluating this combination is underway — HONG KONG and SHANGHAI, China and FLORHA...